Back to top

gene-editing: Archive

Zacks Equity Research

Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition

While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

REGNPositive Net Change NTLANegative Net Change CRSPNegative Net Change DTILPositive Net Change

Ekta Bagri

4 Biotechs That Could Be Potential Takeover Targets in 2022

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

ALNYPositive Net Change BIIBPositive Net Change BMRNPositive Net Change ADAPPositive Net Change CRSPNegative Net Change

Sweta Jaiswal, FRM

How Did Cathie Wood's ARK Invest Perform in 2021?

Let's take a look at how ARK Invest ETFs performed in 2021.

ARKWNegative Net Change ARKQPositive Net Change ARKKNegative Net Change PRNTPositive Net Change ARKGPositive Net Change ARKFNegative Net Change

Ekta Bagri

5 Biotech Stocks That More Than Doubled This Year

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.

DVAXPositive Net Change MRNANegative Net Change PRTAPositive Net Change NTLANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study

Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.

ENDPPositive Net Change NTLANegative Net Change DTILPositive Net Change ISEEPositive Net Change